2024-11-14T20:43:51+00:00 2023-12-31 440160260 Forvis Mazars LLP 8200 W Interstate 10 Suite 900 San Antonio TX 782303806 990 2023-01-01 462216869 Gencure GENC 2107579505 6211 IH 10 WEST SAN ANTONIO TX 78201 John Youngdahl SVP, CFO 2024-11-15 true Robert Ulloa P01953132 2103419400 2024-11-15 2023 2024-10-15 13:58:12Z MARTIN J LANDON 6211 IH 10 WEST SAN ANTONIO TX 78201 5040198 false X WWW.BIOBRIDGEGLOBAL.ORG X 2013 TX GenCure enables progress in the field of advanced therapies (also known as cell & gene therapies) by offering process and analytical (CONTINUED ON SCHEDULE O) 1 0 35 1 0 0 0 0 4996591 5018815 0 0 15818 21383 5012409 5040198 0 0 0 0 3435544 3816983 0 0 0 10285479 11216418 13721023 15033401 -8708614 -9993203 21827142 18815048 14793055 10920765 7034087 7894283 GENCURE IS ORGANIZED TO FOCUS ON REGENERATIVE MEDICINE AND THE UTILIZATION OF THE POWER OF HUMAN CELLS AND TISSUE TO ENHANCE LIVES AND ENABLE CLINICAL ADVANCEMENTS. false false 10041362 0 5040198 GenCure enables progress in the field of advanced therapies (also known as cell & gene therapies) by offering process and analytical development, bioproduction, in-process and release testing, while leveraging a unified quality management system. We partner with our users with the end goal of clinical development in mind, supporting the development of therapies often originating from academic institutions. GenCure's clinical-scale facility opened in March 2020, The bioproduction space is compliant with FDA regulations, EU Annex 1 and PMDA (Grade A, B, C, D). Cleanrooms are sized for a wide range of production volumes and multi-product capabilities, which can meet the need of a variety of research programs. This facility includes 6,700 square feet of cleanroom production space, a 2,500-square-foot development lab, along with office and meeting space. (Continued on Schedule O) 10041362 true false false true false false false false false true false false true true false true true false false false false false false false false false false false true false false false false false false false false false false false false false true true true false false true 13 0 true 35 true false false false false false false false false false false false false X 1 0 false false false false true false false true true false false false true true true true true false false false X Benjamin Lopez 2107579505 6211 IH 10 West San Antonio TX 78201 BIOBRIDGE GLOBAL SOLE MEMBER 1.0 3.0 X 0 0 0 GEOFFREY KINDT General Manager, Biomanufacturing (effective 01/29/23) 50.0 50.0 X 211559 47671 42073 AMANDA WHITELONIS SR. DIRECTOR, PROGRAM MANAGEMENT (through 11/05/23) 50.0 50.0 X 147680 18924 19138 CHRISTIE MALONE SR. DIRECTOR,CUSTOM SOLUTIONS & SALES SUP 25.0 25.0 X 187962 22575 34058 MARI LANE SALMI SR. DIRECTOR, PROCESS DEV & CELL THERAPIES 50.0 0 X 186532 0 36727 MILTON MASAYUKI POLLARD VP, GENCURE OPERATIONS 50.0 0.0 X 253559 0 35097 ROGELIO ZAMILPA SR. DIRECTOR, MFG SCIENCES & TECHNOLOGY 50.0 0 X 209903 0 31260 1197195 89170 198354 11 false true false CAM PHARMACEUTICAL CONSULTING LLC 1100 WOODBROOK WAY GARNER NC 27529 BIOTECH CONSULTING SERVICES 116079 1 0 BIOMANUFACTURING SERVICE FEES 621991 5018815 5018815 0 0 0 0 5018815 0 0 0 0 PURCHASE REBATES 621300 21383 21383 0 0 0 0 0 0 21383 5040198 5040198 0 0 230644 230644 2910572 2910572 154220 154220 297193 297193 224354 224354 221702 221702 0 0 16 16 262652 262652 26963 26963 1030423 1030423 87224 87224 12457 12457 149952 149952 1673927 1673927 9089 9089 SUPPORT & ADMINISTRATIVE FEE 4982950 0 4982950 0 TESTING EXPENSES & SUPPLIES 1770872 1770872 0 0 EQUIPMENT MAINTENANCE 463324 463324 0 0 BAD DEBTS 267162 267162 0 0 257705 257705 0 0 15033401 10041362 4992039 0 138260 154464 2067816 991756 0 0 0 0 1064171 1279936 121668 113427 16909850 5891088 12617843 11018762 0 0 5817384 5256703 21827142 18815048 2614994 593174 0 0 5836922 4159848 6341139 6167743 14793055 10920765 X 7034087 7894283 7034087 7894283 21827142 18815048 X -9993203 10853399 X false true X true false X 369448 245835 0 0 0 615283 15464443 11388400 3990807 5012409 5040198 40896257 0 0 0 15833891 11634235 3990807 5012409 5040198 41511540 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 41511540 210963 0 0 0 0 210963 0 210963 0 0 0 0 210963 0 0 0 0 0 0 0 16044854 11634235 3990807 5012409 5040198 41722503 0.9949 0.9926 0.01 0.0074 X 0 0 0 0 0 0 10041362 0 10041362 0 652068 0 163017 0 0 0 0 0 1000000 681936 836051 652068 3170055 4755083 0 0 0 0 0 250000 170484 209013 163017 792514 1188771 0 0 0 0 0 612187 240309 371878 4056986 1041325 3015661 12083814 4560389 7523425 156863 49065 107798 11018762 INTERCOMPANY RECEIVABLE RIGHT-OF-USE ASSETS - LEASES 5256703 5256703 OPERATING LEASE LIABILITIES 6101629 INTERCOMPANY PAYABLES 66114 6167743 5040198 0 0 0 0 0 5040198 0 0 5040198 15033401 0 0 0 0 0 15033401 0 0 0 15033401 Schedule D, Part X, Line 2 ASC 740 FOOTNOTE MANAGEMENT HAS EVALUATED THEIR INCOME TAX POSITIONS UNDER THE GUIDANCE INCLUDED IN ASC 740. BASED ON THEIR REVIEW, MANAGEMENT HAS NOT IDENTIFIED ANY MATERIAL UNCERTAIN TAX POSITIONS TO BE RECORDED OR DISCLOSED IN THE FINANCIAL STATEMENTS. false false false false false true true false false GEOFFREY KINDT General Manager, Biomanufacturing (effective 01/29/23) 208882 24961 0 22539 2677 171 11183 1698 28956 236 251698 49605 0 0 AMANDA WHITELONIS SR. DIRECTOR, PROGRAM MANAGEMENT (through 11/05/23) 133563 18624 13122 0 995 299 8913 1139 836 8250 157429 28313 0 0 MILTON MASAYUKI POLLARD VP, GENCURE OPERATIONS 225505 0 24093 0 3961 0 13420 0 21678 0 288656 0 0 0 ROGELIO ZAMILPA SR. DIRECTOR, MFG SCIENCES & TECHNOLOGY 183046 0 24702 0 2155 0 12892 0 18367 0 241163 0 0 0 CHRISTIE MALONE SR. DIRECTOR,CUSTOM SOLUTIONS & SALES SUP 167113 22165 18848 0 2002 410 11681 1133 4326 16919 203969 40627 0 0 MARI LANE SALMI SR. DIRECTOR, PROCESS DEV & CELL THERAPIES 167740 0 16638 0 2154 0 4941 0 31786 0 223259 0 0 0 Schedule J, Part I, Line 3 Arrangement used to establish the top management official's compensation THE ORGANIZATION RELIED ON BIOBRIDGE GLOBAL'S PROCESS THAT USED ONE OR MORE OF THE METHODS LISTED IN SCHEDULE J, PART I, LINE 3 TO ESTABLISH THE TOP MANAGEMENT OFFICIAL'S COMPENSATION. Schedule J, Part I, Line 6a Compensation contingent on net earnings of the organization THE ORGANIZATION RELIED ON BIOBRIDGE GLOBAL'S PROCESS OF DETERMINING THE COMPENSATION CONTINGENT ON THE ORGANIZATION'S EARNINGS. THE PROCESS IS DISCLOSED ON THEIR FORM 990. Schedule J, Part I, Line 6b Compensation contingent on net earnings of a related organization THE ORGANIZATION RELIED ON BIOBRIDGE GLOBAL'S PROCESS OF DETERMINING THE COMPENSATION CONTINGENT ON THE ORGANIZATION'S EARNINGS. THE PROCESS IS DISCLOSED ON THEIR FORM 990. Form 990, Part I, Line 1 Brief Mission GenCure enables progress in the field of advanced therapies (also known as cell & gene therapies) by offering process and analytical development, bioproduction; in-process and release testing, while leveraging a unified quality management system. We partner with our users with the end goal of clinical development in mind, supporting development of therapies often originating from academic research institutions. Form 990, Part III, Line 4a DESCRIPTION OF ORGANIZATION'S MISSION OR MOST SIGNIFICANT ACTIVITIES GenCure enables progress in the field of advanced therapies (also known as cell & gene therapies) by offering process and analytical development, bioproduction, in-process and release testing, while leveraging a unified quality management system. We partner with our users with the end goal of clinical development in mind, supporting the development of therapies often originating from academic institutions. GenCure's clinical-scale facility opened in March 2020, The bioproduction space is compliant with FDA regulations, EU Annex 1 and PMDA (Grade A, B, C, D). Cleanrooms are sized for a wide range of production volumes and multi-product capabilities, which can meet the need of a variety of research programs. This facility includes 6,700 square feet of cleanroom production space, a 2,500-square-foot development lab, along with office and meeting space. Internally, GenCure utilizes electronic batch records using the MasterControl platform. The automation of the electronic batch record has demonstrated improved efficiency with regards to record completion, review, and approval, while maintaining a high level of compliance for document control. Regarding workforce development, the GenCure team expanded to include personnel from the local area through a partnership with the San Antonio for Growth on the Eastside organization. The GenCure team continues to increase the community support by actively participating in the Step into Stem program sponsored by Texas Research and Technology Foundation which provides mentoring to local students to increase awareness for STEM-based careers. The GenCure team has grown, in terms of personnel and capabilities, to meet the needs of our researchers developing these novel cures for oncology and rare diseases. Form 990, Part VI, Line 8a DOCUMENTATION OF MEETINGS OR WRITTEN ACTIONS BY THE GOVERNING BODY MEETINGS HELD AND WRITTEN ACTIONS UNDERTAKEN WERE DOCUMENTED IN THE MINUTES OF THE MEETINGS OF BIOBRIDGE GLOBAL'S BOARD OF DIRECTORS. Form 990, Part VI, Line 15a REVIEW OF CEO/TOP MANAGEMENT COMPENSATION IN DETERMINING THE TOP MANAGEMENT OFFICIAL'S COMPENSATION, THE ORGANIZATION RELIED ON BIOBRIDGE GLOBAL'S PROCESS TO ASSIST IN COMPENSATION DECISIONS. THE PROCESS OF DETERMINING THE TOP MANAGEMENT COMPENSATION IS DISCLOSED ON THEIR FORM 990. Form 990, Part VI, Line 15b REVIEW OF OTHER OFFICER'S COMPENSATION THE ORGANIZATION RELIED ON BIOBRIDGE GLOBAL'S PROCESS TO ASSIST IN COMPENSATION DECISIONS. THE PROCESS OF DETERMINING OTHER OFFICER'S COMPENSATION IS DISCLOSED ON THEIR FORM 990. Form 990, Part VI, Line 6 Classes of members or stockholders BIOBRIDGE GLOBAL IS THE SOLE MEMBER OF THE CORPORATION. Form 990, Part VI, Line 11b Review of form 990 by governing body THE ORGANIZATION ENGAGES AN OUTSIDE ACCOUNTING FIRM TO PREPARE THE FORM 990. ONCE PREPARED, THE RETURN IS REVIEWED BY THE FINANCIAL MANAGEMENT STAFF FROM BIOBRIDGE GLOBAL, A RELATED ORGANIZATION. A COPY OF THE FORM 990 IS PROVIDED TO THE EXECUTIVE COMMITTEE OF THE BOARD OF DIRECTORS OF BIOBRIDGE GLOBAL PRIOR TO FILING. Form 990, Part VI, Line 12c Conflict of interest policy A COPY OF THE ORGANIZATION'S CONFLICT OF INTEREST POLICY IS PROVIDED ANNUALLY TO ALL OFFICERS, KEY EMPLOYEES, AND BOARD OF DIRECTORS OF BIOBRIDGE GLOBAL. IN ADDITION, QUESTIONNAIRES ARE GIVEN OUT ON AN ANNUAL BASIS TO ALL OFFICERS, KEY EMPLOYEES AND BOARD OF DIRECTORS WHICH COVER BUSINESS AND FAMILY RELATIONSHIPS AND VARIOUS ACTIVITIES THAT HAVE OCCURRED OVER THE COURSE OF THE YEAR. EVERY ATTEMPT IS MADE TO ENSURE THAT ALL FORMS ARE RETURNED. INDIVIDUALS WHO FAIL TO RETURN THE REQUESTED FORMS OR PROVIDE INCOMPLETE INFORMATION ARE CONTACTED BY THE ORGANIZATION. IN THE EVENT OF A CONFLICT OF INTEREST, THE MEMBER SUBJECT TO THE CONFLICT OF INTEREST MUST LEAVE THE DISCUSSION AND VOTING ON A TRANSACTION OR ARRANGEMENT THAT RESULTS IN A CONFLICT OF INTEREST. A COMMITTEE OF NON-INTERESTED REPRESENTATIVES SHALL BE APPOINTED TO INVESTIGATE ALTERNATIVES TO THE PROPOSED TRANSACTION OR ARRANGEMENT. THE PARTY WITH A CONFLICT OF INTEREST IS NOT PERMITTED TO ADVOCATE TO OTHER REPRESENTATIVES PRIOR TO THE VOTE. THE COMMITTEE IS RESPONSIBLE FOR EXERCISING DUE DILIGENCE IN DETERMINING THAT THE TRANSACTION IS NOT MORE MATERIALLY ADVANTAGEOUS THAN A DEAL WITH A NON-INTERESTED TRANSACTION. Form 990, Part VI, Line 19 Required documents available to the public ANY DOCUMENTS SUBJECT TO OPEN RECORD REQUIREMENTS ARE MADE AVAILABLE UPON REQUEST. Form 990, Part XI, Line 9 Other changes in net assets or fund balances EQUITY TRANSFER BETWEEN RELATED ORGANIZATIONS - 10853399; SOUTH TEXAS BLOOD & TISSUE CENTER 6211 IH 10 WEST SAN ANTONIO TX 78201 237379332 BLOOD BANK TX 501(c)(3) 10 See Part VII true THE BLOOD & TISSUE CENTER FOUNDATION 6211 IH 10 WEST SAN ANTONIO TX 78201 431970952 SUPPORT ORG. TX 501(c)(3) Type I See Part VII true BIOBRIDGE GLOBAL 6211 IH 10 WEST SAN ANTONIO TX 78201 454765222 SUPPORT ORG. TX 501(c)(3) Type II NA false QUALTEX LABORATORIES 6211 IH 10 WEST SAN ANTONIO TX 78201 208429619 TEST PUBLIC SAFETY AZ 501(c)(3) 11 See Part VII true false false false false true false false false false false false false true true true true true true true SOUTH TEXAS BLOOD & TISSUE CENTER S 3952841 BOOK COST QUALTEX LABORATORIES S 595338 BOOK COST QUALTEX LABORATORIES M 483134 BOOK COST Schedule R, Part II, Column (f) DIRECT CONTROLLING ENTITY THE ORGANIZATIONS SPECIFIED ARE ALL CONTROLLED BY BIOBRIDGE GLOBAL.